77 results
8-K
EX-99.1
BEAM
Beam Therapeutics Inc
7 May 24
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
7:09am
.
Research & Development (R&D) Expenses: R&D expenses were $84.8 million for the first quarter of 2024, compared to $99.6 million for the first … and collaboration revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other
S-3ASR
BEAM
Beam Therapeutics Inc
27 Feb 24
Automatic shelf registration
6:10pm
;
the initiation, timing, progress and results of our clinical trials;
the initiation, timing, progress and results of our research and development programs … for research and development activities, including preclinical study and clinical trial expenses; acquisitions or licenses of products, product candidates
8-K
EX-99.1
zcdvbeh3z2czcib1c6t
27 Feb 24
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
6:43am
8-K
EX-99.1
gjcztu6aye0gh2m7
8 Jan 24
Results of Operations and Financial Condition
6:55am
8-K
EX-99.1
hb6b2s lk
8 Nov 23
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
7:00am
8-K
EX-99.1
7p0kn2y
19 Oct 23
Cost Associated with Exit or Disposal Activities
8:50am
CORRESP
hih92wttx47stfg
9 Aug 23
Correspondence with SEC
12:00am
8-K
EX-99.1
tkkah6 ra1t5w3t
8 Aug 23
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
7:11am
424B5
3wumebwdck21vc9krum
10 May 23
Prospectus supplement for primary offering
5:10pm
8-K
EX-99.1
hslvh
10 May 23
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
7:00am
8-K
EX-99.1
s0oaj2o yquum
7 Nov 22
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
7:00am
8-K
q1xm2kt10myg
7 Sep 22
Other Events
6:47am